Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma.

Allen BG, Bodeker KL, Smith MC, Monga V, Sandhu S, Hohl R, Carlisle T, Brown H, Hollenbeck N, Vollstedt S, Greenlee JD, Howard MA, Mapuskar KA, Seyedin SN, Caster JM, Jones KA, Cullen JJ, Berg D, Wagner BA, Buettner GR, TenNapel MJ, Smith BJ, Spitz DR, Buatti JM.

Clin Cancer Res. 2019 Nov 15;25(22):6590-6597. doi: 10.1158/1078-0432.CCR-19-0594. Epub 2019 Aug 19.

PMID:
31427282
2.

Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer.

Alexander MS, Wilkes JG, Schroeder SR, Buettner GR, Wagner BA, Du J, Gibson-Corley K, O'Leary BR, Spitz DR, Buatti JM, Berg DJ, Bodeker KL, Vollstedt S, Brown HA, Allen BG, Cullen JJ.

Cancer Res. 2018 Dec 15;78(24):6838-6851. doi: 10.1158/0008-5472.CAN-18-1680. Epub 2018 Sep 25.

3.

O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Kauffman EPS, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG.

Cancer Cell. 2017 Aug 14;32(2):268. doi: 10.1016/j.ccell.2017.07.008. No abstract available.

4.

Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience of Two Phase 1 Clinical Trials.

Zahra A, Fath MA, Opat E, Mapuskar KA, Bhatia SK, Ma DC, Rodman SN III, Snyders TP, Chenard CA, Eichenberger-Gilmore JM, Bodeker KL, Ahmann L, Smith BJ, Vollstedt SA, Brown HA, Hejleh TA, Clamon GH, Berg DJ, Szweda LI, Spitz DR, Buatti JM, Allen BG.

Radiat Res. 2017 Jun;187(6):743-754. doi: 10.1667/RR14668.1. Epub 2017 Apr 24.

5.

O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG.

Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268.

6.

Hypoglycin A Content in Blood and Urine Discriminates Horses with Atypical Myopathy from Clinically Normal Horses Grazing on the Same Pasture.

Bochnia M, Ziegler J, Sander J, Uhlig A, Schaefer S, Vollstedt S, Glatter M, Abel S, Recknagel S, Schusser GF, Wensch-Dorendorf M, Zeyner A.

PLoS One. 2015 Sep 17;10(9):e0136785. doi: 10.1371/journal.pone.0136785. eCollection 2015.

7.

[Between empiricism and evidence - ( re ) activation of veterinary phytotherapy].

Walkenhorst M, Vogl CR, Vogl-Lukasser B, Vollstedt S, Brendieck-Worm C, Ivemeyer S, Klarer F, Meier B, Schmid K, Disler M, Bischoff T, Hamburger M, Häsler S, Stöger E.

Forsch Komplementmed. 2014;21 Suppl 1:35-42. doi: 10.1159/000362396. Epub 2014 Jul 4. German. No abstract available.

8.

Phenotype and function of neonatal DC.

Willems F, Vollstedt S, Suter M.

Eur J Immunol. 2009 Jan;39(1):26-35. doi: 10.1002/eji.200838391. Review.

9.

No evidence for association between the interferon regulatory factor 1 (IRF1) gene and clinical tuberculosis.

Vollstedt S, Yuliwulandari R, Okamoto K, Lien LT, Keicho N, Rochani JT, Wikaningrum R, Tokunaga K.

Tuberculosis (Edinb). 2009 Jan;89(1):71-6. doi: 10.1016/j.tube.2008.09.006. Epub 2008 Nov 22.

PMID:
19028144
10.

The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4+ T cells.

Kano S, Sato K, Morishita Y, Vollstedt S, Kim S, Bishop K, Honda K, Kubo M, Taniguchi T.

Nat Immunol. 2008 Jan;9(1):34-41. Epub 2007 Dec 2.

PMID:
18059273
11.

The long-term but not the short-term antiviral effect of IFN-alpha depends on Flt3 ligand and pDC.

Vollstedt S, O'Keeffe M, Ryf B, Glanzmann B, Hochrein H, Suter M.

Eur J Immunol. 2006 May;36(5):1231-40.

12.

Treatment of neonatal mice with Flt3 ligand leads to changes in dendritic cell subpopulations associated with enhanced IL-12 and IFN-alpha production.

Vollstedt S, O'Keeffe M, Odermatt B, Beat R, Glanzmann B, Riesen M, Shortman K, Suter M.

Eur J Immunol. 2004 Jul;34(7):1849-60.

13.

Dendritic cells from mice neonatally vaccinated with modified vaccinia virus Ankara transfer resistance against herpes simplex virus type I to naive one-week-old mice.

Franchini M, Hefti H, Vollstedt S, Glanzmann B, Riesen M, Ackermann M, Chaplin P, Shortman K, Suter M.

J Immunol. 2004 May 15;172(10):6304-12.

14.

Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1.

Vollstedt S, Arnold S, Schwerdel C, Franchini M, Alber G, Di Santo JP, Ackermann M, Suter M.

J Virol. 2004 Apr;78(8):3846-50.

15.

Flt3 ligand-treated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections.

Vollstedt S, Franchini M, Hefti HP, Odermatt B, O'Keeffe M, Alber G, Glanzmann B, Riesen M, Ackermann M, Suter M.

J Exp Med. 2003 Mar 3;197(5):575-84.

Supplemental Content

Loading ...
Support Center